Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leinonen, E. S.
Right arrow Articles by Taskinen, M.-R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Leinonen, E. S.
Right arrow Articles by Taskinen, M.-R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 26:1654-1655, 2003
© 2003 by the American Diabetes Association, Inc.

Letters: Comments and Responses
Letter

IGF Binding Protein-1 and Carotid Intima-Media Thickness in Type 2 Diabetes

Response to Conti et al.

Eeva S. Leinonen, MD1, Pekka J. Leinonen, MD, PHD2 and Marja-Riitta Taskinen, MD, PHD1

1 Department of Internal Medicine, Helsinki University Central Hospital, Helsinki, Finland
2 Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland

We thank Conti et al. (1) for their interest in our recent article (2) and the editor for the opportunity to further discuss the role of the IGF system in atherosclerosis.

We found an inverse relation between IGF binding protein-1 (IGFBP-1) and carotid intima-media thickness (IMT) in type 2 diabetic patients. In the linear regression model for diabetic subjects with cardiovascular disease (CVD), IGFBP-1 was one of the main determinants of IMT (standardized coefficient ß = -0.353, P = 0.027) together with age, Apo B, and pulse pressure; other determinants were diabetes duration, smoking, BMI, sex, and lipoprotein [Lp(a)]. This model explained 57.3% of maximum IMT variation. IGFBP-1 also remained in the linear regression model for IMT in subjects without CVD. Our cross-sectional study setting does not allow the interpretation to which extent these associations are causal. In agreement with previous data (3), IGFBP-1 concentration was inversely related to insulin resistance examined by homeostasis model assessment.

On the contrary, after adjusting for confounders, we found no association between total IGF-I and either IMT or presence of CVD. This indicates the relation between IGFBP-1 and IMT to be independent of IGF-I. Our results underline IGFBP-1 as a marker of insulin resistance and the metabolic syndrome, but this cannot be extrapolated to reflect an IGF-I effect on the vasculature. Similarly, Heald et al. (4) demonstrated an inverse correlation between IGFBP-1, but not IGF-I, and clinical cardiovascular disease in type 2 diabetic subjects.

Another finding was the positive correlation of total IGF-I with LDL cholesterol and Lp(a) and IGFBP-3 with LDL cholesterol, Lp(a), total cholesterol, and Apo B after controlling for age, sex, BMI, and diabetes duration. Thus, in hypercholesterolemic diabetic patients the IGF axis seems to be activated.

The relation of the IGF system to CVD is complex and awaits a conclusive answer after over 1,000 published articles (5). Therefore, we agree with Conti et al. that further research is needed to understand the entire picture.

Footnotes

Address correspondence to Professor Marja-Riitta Taskinen, Helsinki University Hospital, Biomedicum, Haartmaninkatu 8, P.O. Box 700, 00029 Helsinki, Finland. E-mail: mataskin{at}helsinki.fi.

References

  1. Conti E, Pitocco D, Capoluongo E, Zuppi C, Ghirlanda G, Crea F, Andreotti F: IGF-1 and macrovascular complications of diabetes: alternative interpretations of recently published data (Letter). Diabetes Care 26:1653–1654, 2003[Free Full Text]
  2. Leinonen ES, Salonen JT, Salonen RM, Koistinen RA, Leinonen PJ, Sarna SS, Taskinen MR: Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care 25:1807–1812, 2002[Abstract/Free Full Text]
  3. Mohamed-Ali V, Pinkney JH, Panahloo A, Cwyfan-Hughes S, Holly JM, Yudkin JS: Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome. Clin Endocrinol (Oxf) 50:221–228, 1999[Medline]
  4. Heald AH, Siddals KW, Fraser W, Taylor W, Kaushal K, Morris J, Young RJ, White A, Gibson JM: Low circulating levels of IGF binding protein-1 are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 51:2629–2636, 2002[Abstract/Free Full Text]
  5. Frystyk J, Ledet T, Møller N, Flyvbjerg A, Ørskov H: Cardiovascular disease and insulin-like growth factor I. Circulation 106:893–895, 2002[Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leinonen, E. S.
Right arrow Articles by Taskinen, M.-R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Leinonen, E. S.
Right arrow Articles by Taskinen, M.-R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum